Results of Open Label Study of NE3107 in Alzheimer’s Disease

Results of Open Label Study of NE3107 in Alzheimer’s Disease

82% of MCI and mild AD patients had improvements in their modified ADAS-Cog12 score

Format

PNG

Source

BioVie, Inc.

Downloads